Biofidelity, a leader in advanced genomic technologies, has formed a partnership with CellCarta, a globally renowned contract research organization (CRO) known for its expertise in precision medicine. Together, they aim to introduce Biofidelity’s Aspyre® Lung into clinical trials worldwide.
Aspyre Lung streamlines the process of identifying essential biomarkers for non-small cell lung cancer (NSCLC) by efficiently analyzing DNA and RNA from both tissue and blood samples in just four straightforward steps. Designed to be compatible with existing qPCR platforms, it integrates seamlessly into laboratories around the globe, supporting CellCarta’s mission to advance precision medicine through innovative genomic solutions.
As part of this collaboration, CellCarta will first implement and validate Aspyre Lung in its European laboratories, followed by its U.S.-based facilities, with non-exclusive rights to deploy this technology in clinical trials worldwide. This partnership equips researchers with cutting-edge tools to utilize both liquid and tissue biopsies, accelerating clinical trial enrollment and ensuring more reliable results.
“We’re excited to partner with CellCarta to introduce Aspyre Lung to clinical trials worldwide,” said Dr. Barnaby Balmforth, Co-Founder and CEO of Biofidelity. “Our goal at Biofidelity is to ensure that the transformative benefits of genomics are accessible to people across the globe. By combining our Simplified Genomic Profiling (SGP) technology with CellCarta’s extensive network, we are making significant strides toward achieving this vision.”
Dusty Tenney, CEO of CellCarta, expressed similar enthusiasm: “This partnership with Biofidelity perfectly aligns with our mission to advance precision medicine. Adding Aspyre Lung to our biomarker testing portfolio enhances our ability to deliver tailored solutions for the pharmaceutical and biotech industries.”
This collaboration represents a significant step forward in global efforts to accelerate innovation and improve access to clinical research and precision medicine.